Drug
NIO752 clinical trials
Also written NIO752.
- studies test it
- 3
- open now
- 2
- in phase 3
- 0
- first study started
- 2023
Keep track of what changes. Save the NIO752 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Novartis Pharmaceuticals (2) · University College, London (1)
Studies
Open first, then newest update. How each study uses NIO752 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary TauopathiesNot yet recruitingPhase 2Novartis PharmaceuticalsNCT07868328Written as NIO752
- A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILKRecruitingPhase 1University College, LondonNCT06372821Written as NIO752
- Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive, not recruitingPhase 1Novartis PharmaceuticalsNCT05469360Written as NIO752